Clinical trials
Aortic Valve Disease trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
25 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2021 | 4 |
| 2022 | 5 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 11 |
| Unknown status | 6 |
| Completed | 4 |
| Not yet recruiting | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Xijing Hospital | 3 |
| Chinese Academy of Medical Sciences, Fuwai Hospital | 2 |
| Genesis Medtech Corporation | 2 |
| Nanjing First Hospital, Nanjing Medical University | 2 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Sun Yat-sen University | 2 |
| Abbott Medical Devices | 1 |
| Corcym S.r.l | 1 |
| Han Yaling, MD | 1 |
| JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Aortic Valve Disease | 25 |
| Aortic Valve Stenosis | 11 |
| Aortic Valve Insufficiency | 5 |
| Heart Valve Diseases | 3 |
| Mitral Valve Stenosis | 2 |
| Bicuspid Aortic Valve Disease | 1 |
| Cardiovascular Diseases | 1 |
| Gastroesophageal Reflux | 1 |
| Heart Diseases | 1 |
| Heart Failure | 1 |
Trials
Showing 1 to 25 of 25. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.